Gossamer Bio, Inc.GOSS

Gossamer Bio is a clinical-stage outfit trying to turn a dry-powder inhaler called seralutinib into a therapy for pulmonary arterial hypertension and pulmonary hypertension in interstitial lung disease. The drug is designed to block PDGFRα/β, CSF1R, and c‑KIT receptors, which sounds precise until you notice the company has not yet turned those receptors into revenue large enough to cover a single $2.7 billion acquisition. The product page and team bios read like a who’s-who of ex-Actelion and Biomarin talent, but the financials are still in the start-up phase-only with the liabilities of a scale-up. (product image)

The most recent SEC filing is the 10-Q for the quarter ended 31 March 2026, which shows revenue of $17.0 million, a net loss of $46.7 million, and a diluted loss per share of $0.20. Cash and equivalents fell to $41.0 million while liabilities reached $290.4 million, leaving shareholders’ equity at -$161.5 million. Net cash used in operating activities was $38.7 million for the quarter, and the company reported zero capex-because when your factories are PowerPoint slides, you don’t need plant, property, or equipment. (10-Q, 31 Mar 2026)

Seralutinib remains an investigational new drug; no regulatory approvals have been granted and no sales are booked outside clinical trials. The company’s press releases trumpet milestones and financings, but the only metric that matters-cash runway-is still measured in single-digit quarters. A June 2026 8-K disclosed a $30 million private placement convertible note due 2029, which bought time but did not erase the deficit. The team page boasts ex-Actelion hands who launched PAH franchises, yet the financials still look like a biotech pre-clinical spin-out rather than a post-launch royalty machine. (team bios) (8-K, 1 Jul 2026)

If you want a chart route, the company’s XBRL company facts endpoint is the cleanest source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001728117.json. That JSON file lists every filed data point with source tags; it is the closest thing to a real-time balance sheet the market gets. There is no trading-view chart to cite because the evidence rail does not supply price levels or volumes.

The filing rhythm is now dominated by Schedule 13D amendments: the group first crossed 5% on 11 June 2026, then filed an original schedule on 1 July, an amendment on 1 July, and another amendment on 24 July. The disclosures do not reveal the economic terms, only the ownership percentages, so the market is left to guess whether the next shoe is a block trade, a block purchase, or a block structured convertible. (Schedule 13D, 11 Jun 2026) (13D/A, 1 Jul 2026) (13D/A, 24 Jul 2026)

What remains unproven is any repeatable revenue line outside R&D reimbursements, any regulatory approval, and any path to sustained solvency without further dilution. The evidence rail does not include a marketed drug, a marketed device, or a supply agreement large enough to matter. Until then, the company’s most tangible asset is a set of clinical protocols, a convertible note due in 2029, and a management desks calendar that is currently pencilled in for the next financing.